Sirolimus for the treatment of vascular tumors and malformations in children: A 10-year single-institution retrospective study

Figure 1 Kaplan-Meier analysis of progression-free survival in children with vascular tumors and vascular malformations treated with sirolimus. Two progression events occurred in patients with kaposiform hemangioendothelioma after discontinuation of sirolimus. VT: Vascular tumors; VM: Vascular malformations.

Figure 2 Magnetic resonance imaging of a patient with composite hemangioendothelioma before and after sirolimus therapy. A: Baseline post-contrast T1-weighted image with fat suppression in the coronal view demonstrating a large heterogeneous mass with areas of necrosis involving the nasal cavity, sphenoid sinuses, and ethmoid sinuses (arrows); B: Follow-up magnetic resonance imaging obtained after 6 months of sirolimus therapy showing a marked reduction in tumor size (arrows).